Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nucel Biotecnologia is a Brazilian biotechnology company specializing in the development and production of recombinant human proteins and advanced cell therapies. Originally established as a spin-off from the University of São Paulo (USP), the company operates at the intersection of academic research and industrial biomanufacturing. Its primary focus is on creating high-value biosimilars and innovative biological treatments for complex conditions such as hemophilia, multiple sclerosis, and chronic kidney disease. Nucel's infrastructure includes state-of-the-art laboratories for molecular biology and large-scale cell culture, positioning it as a key player in South America's biologics sector. The company also engages in cutting-edge research into stem cell applications for neurodegenerative and metabolic disorders.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NuCel.